The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Emerging strategies to manage kidney disease in SCD patients
In this video, Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, briefly discusses strategies to manage kidney disease in patients with sickle cell disease (SCD). Dr Saraf first discusses current and emerging agents, including hydroxyurea, ACE inhibitors, and voxelotor, and further highlights the need for more targeted therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding support from FORMA, Global Blood Therapeutics, Novartis, and Pfizer
Serves as a consultant or on an advisory board for Agios, FORMA, Global Blood Therapeutics, Novartis, and ORIC.
